G protein-coupled oestrogen receptor (GPER) expression and correlation with survival in cancer (a) RNA-seq data from cancer types downloaded from TCGA cBioPortal (http://www.cbioportal.org/index.do), 11/2017 and 2/2018. Gene abundance quantified as RNA-seq by Expectation Maximisation). p values from Wilcoxon rank-sum test. BRCA—breast invasive carcinoma, LIHC—liver hepatocellular carcinoma, LUAD—lung adenocarcinoma, STAD—stomach adenocarcinoma, UCEC—uterine corpus endometrial carcinoma, KICH—kidney chromophobe, STES—stomach and esophageal carcinoma, and COADREAD—colorectal adenocarcinoma. Number of patients/normal—BRCA (1093/112), LIHC (371/50), LUAD (515/59), STAD (415/35), UCEC (545/35), KICH (66/25), STES (599/46), COADREAD (623/51). (b) Survival curves for cancer patients, divided into high and low expression determined using median gene expression of GPER. p values from Kaplan–Meier statistical test. PDAC—pancreatic ductal adenocarcinoma, and KIRC—Kidney renal clear cell carcinoma. For PDAC, BRCA, UCEC and KIRC, n = 177, 1090, 543, 532 patients respectively. (c) Relapse-free probability curves for PDAC and KIRC cancer patients. High and low expression determined using median gene expression of GPER. p value from Kaplan–Meier statistical test, For PDAC, KIRC n = 138, 434 patients. (d) Immunofluorescence images of GPER (green), actin (red), and DAPI (blue) in Suit2-007 cells. Scale bar = 25 µm. (e) Immunofluorescence images of GPER (green), actin (red), and DAPI (blue) in PC-3 cells. Scale bar = 25 µm. (f) Immunofluorescence images of GPER (green), cytokeratin 19 (red) and DAPI (blue) in PDAC patients. Scale bar = 100 µm. (g) Western blot for GPER and total protein in untreated SUIT2 cells (Control), SUIT2 cells with siRNA to GPER (siGPER) and HEK293 cells. Quantification of GPER (ab154069) normalised to total protein. Mean ± s.e.m. with individual values overlaid (n = 3); one-way ANOVA with Dunnett pairwise comparisons. ** p < 0.01, *** p < 0.001. Full blot images in Supplementary Figure S1.